RESUMEN
Mumps is a vaccine-preventable acute viral infectious disease. To understand the incidence of mumps and population immunity in Quzhou City after measles mumps rubella vaccine (MMR) was included in the immunization program, we analyzed the epidemiological characteristics of mumps cases from 2009 to 2023 and a cross-sectional serosurvey of IgG antibodies to mumps conducted in 2024. We found that 15 years after the MMR vaccine was included in the immunization program, the incidence of mumps was significantly reduced in all populations, but the incidence remained highest in vaccinated children aged 0-12 years. Vaccine escape may explain the high incidence of mumps in highly vaccinated populations. Updating vaccines or developing a new vaccine that targets multiple viral genotypes may be necessary to improve the effectiveness of the vaccine against infection and fully control infections and outbreaks. The positive rate and concentration of mumps IgG antibody were inconsistent with the incidence data. mumps IgG antibody is not an ideal substitute for immunity and cannot be used to accurately predict whether a target population is susceptible or protected. Natural infections may provide longer-lasting immunity than vaccination.
Asunto(s)
Anticuerpos Antivirales , Programas de Inmunización , Inmunoglobulina G , Vacuna contra el Sarampión-Parotiditis-Rubéola , Paperas , Humanos , Paperas/epidemiología , Paperas/prevención & control , Paperas/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Preescolar , Lactante , Anticuerpos Antivirales/sangre , Niño , Femenino , Incidencia , Adolescente , Inmunoglobulina G/sangre , Masculino , Estudios Transversales , Adulto Joven , Adulto , China/epidemiología , Estudios Seroepidemiológicos , Persona de Mediana Edad , Virus de la Parotiditis/inmunología , Virus de la Parotiditis/genética , Recién NacidoRESUMEN
As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to develop intranasal, broadly protective vaccines. Here, we developed highly efficacious, intranasal trivalent SARS-CoV-2 vaccine candidates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jeryl Lynn (JL1) strain, and MuV JL2 strain. Specifically, MeV, MuV-JL1, and MuV-JL2 vaccine strains, each expressing prefusion spike (preS-6P) from a different variant of concern (VoC), were combined to generate TVCs. Intranasal immunization of IFNAR1-/- mice and female hamsters with TVCs generated high levels of S-specific serum IgG antibodies, broad neutralizing antibodies, and mucosal IgA antibodies as well as tissue-resident memory T cells in the lungs. The immunized female hamsters were protected from challenge with SARS-CoV-2 original WA1, B.1.617.2, and B.1.1.529 strains. The preexisting MeV and MuV immunity does not significantly interfere with the efficacy of TVC. Thus, the trivalent platform is a promising next-generation SARS-CoV-2 vaccine candidate.
Asunto(s)
Administración Intranasal , Anticuerpos Neutralizantes , Anticuerpos Antivirales , Vacunas contra la COVID-19 , COVID-19 , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus , Animales , Glicoproteína de la Espiga del Coronavirus/inmunología , Glicoproteína de la Espiga del Coronavirus/genética , Femenino , SARS-CoV-2/inmunología , SARS-CoV-2/genética , COVID-19/prevención & control , COVID-19/inmunología , COVID-19/virología , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/sangre , Anticuerpos Neutralizantes/inmunología , Anticuerpos Neutralizantes/sangre , Ratones , Vacunas contra la COVID-19/inmunología , Vacunas contra la COVID-19/administración & dosificación , Cricetinae , Humanos , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Virus del Sarampión/inmunología , Virus del Sarampión/genética , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Virus de la Parotiditis/inmunología , Virus de la Parotiditis/genética , Ratones Noqueados , Mesocricetus , Inmunoglobulina A/inmunología , Inmunoglobulina A/sangreRESUMEN
Mumps is a vaccine-preventable disease with high contagious capability. Its incidence declined rapidly since one dose of mumps vaccine was introduced into Expanded Program of Immunization (EPI) in 2008 in China. Nonetheless, the outbreaks of mumps remain frequent in China. Here we aim to assess herd immunity level followed by one-dose mumps ingredient vaccine and to elucidate the genetic characteristics of mumps viruses circulating in the post vaccine era in Jiangsu province of China. The complete sequences of mumps virus small hydrophobic(SH) gene were amplified and sequenced; coalescent-based Bayesian method was used to perform phylogenetic analysis with BEAST 1.84 software. Commercially available indirect enzyme-linked immune-sorbent IgG assay was used for the quantitative detection of IgG antibody against mumps virus. Our results show that genotype F was the predominant mumps viruses and belonged to indigenous spread, and most of Jiangsu sequences clustered together and formed a monophyly. The prevalence of mumps reached a peak in 2012 and subsequently declined, which presented an obvious different trajectory with virus circulating in other regions of China. The gene diversity of viruses circulating in Jiangsu province was far less than those in China. The antibody prevalence reached 70.42% in the general population during 2018 to 2020. The rising trend of antibody level was also observed. Although mumps antibody prevalence does not reach expected level, mumps virus faces higher pressure in Jiangsu province than the whole of China. To reduce further the prevalence of mumps viruses, two doses of mumps vaccine should be involved into EPI.
Asunto(s)
Anticuerpos Antivirales , Vacuna contra la Parotiditis , Virus de la Parotiditis , Paperas , Filogenia , Virus de la Parotiditis/genética , Virus de la Parotiditis/inmunología , Virus de la Parotiditis/clasificación , Humanos , China/epidemiología , Paperas/epidemiología , Paperas/virología , Paperas/inmunología , Paperas/prevención & control , Anticuerpos Antivirales/sangre , Vacuna contra la Parotiditis/administración & dosificación , Vacuna contra la Parotiditis/inmunología , Adulto , Adulto Joven , Femenino , Masculino , Genotipo , Adolescente , Niño , Inmunoglobulina G/sangre , Persona de Mediana Edad , Preescolar , Inmunidad Colectiva , Variación Genética , Proteínas ViralesRESUMEN
With the rapid increase in SARS-CoV-2 cases in children, a safe and effective vaccine for this population is urgently needed. The MMR (measles/mumps/rubella) vaccine has been one of the safest and most effective human vaccines used in infants and children since the 1960s. Here, we developed live attenuated recombinant mumps virus (rMuV)-based SARS-CoV-2 vaccine candidates using the MuV Jeryl Lynn (JL2) vaccine strain backbone. The soluble prefusion SARS-CoV-2 spike protein (preS) gene, stablized by two prolines (preS-2P) or six prolines (preS-6P), was inserted into the MuV genome at the P-M or F-SH gene junctions in the MuV genome. preS-6P was more efficiently expressed than preS-2P, and preS-6P expression from the P-M gene junction was more efficient than from the F-SH gene junction. In mice, the rMuV-preS-6P vaccine was more immunogenic than the rMuV-preS-2P vaccine, eliciting stronger neutralizing antibodies and mucosal immunity. Sera raised in response to the rMuV-preS-6P vaccine neutralized SARS-CoV-2 variants of concern, including the Delta variant equivalently. Intranasal and/or subcutaneous immunization of IFNAR1-/- mice and golden Syrian hamsters with the rMuV-preS-6P vaccine induced high levels of neutralizing antibodies, mucosal immunoglobulin A antibody, and T cell immune responses, and were completely protected from challenge by both SARS-CoV-2 USA-WA1/2020 and Delta variants. Therefore, rMuV-preS-6P is a highly promising COVID-19 vaccine candidate, warranting further development as a tetravalent MMR vaccine, which may include protection against SARS-CoV-2.
Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Vacuna contra el Sarampión-Parotiditis-Rubéola , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus , Eficacia de las Vacunas , Animales , Anticuerpos Neutralizantes/sangre , Anticuerpos Antivirales/sangre , COVID-19/prevención & control , Vacunas contra la COVID-19/genética , Vacunas contra la COVID-19/inmunología , Inmunogenicidad Vacunal , Vacuna contra el Sarampión-Parotiditis-Rubéola/genética , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Mesocricetus , Ratones , Virus de la Parotiditis/genética , Virus de la Parotiditis/inmunología , Prolina/genética , SARS-CoV-2/genética , SARS-CoV-2/inmunología , Glicoproteína de la Espiga del Coronavirus/genética , Glicoproteína de la Espiga del Coronavirus/inmunología , Vacunas Atenuadas/genética , Vacunas Atenuadas/inmunologíaRESUMEN
This case involved a 72-year-old woman. From the day after mitral annuloplasty, a fever over 37°C and ballismus-like involuntary movements of the right upper and lower limbs appeared. A few month later, involuntary movements spread throughout the body, and she developed impairment of consciousness and difficulty speaking and eating. Levels of protein in cerebrospinal fluid were high. Positive results were seen for serum mumps immunoglobulin G and M antibody. Because steroid pulse therapy proved effective, we suspected autoimmune encephalitis associated with mumps virus infection.
Asunto(s)
Discinesias , Encefalitis , Paperas , Anciano , Encefalitis/complicaciones , Encefalitis/etiología , Femenino , Enfermedad de Hashimoto , Humanos , Inmunoglobulina G , Paperas/complicaciones , Paperas/diagnóstico , Paperas/inmunología , Virus de la Parotiditis/inmunologíaRESUMEN
Despite high levels of MMR-II usage in the US, mumps outbreaks continue to occur. Evidence suggests that mumps vaccine-induced humoral immunity wanes over time. Relatively few studies have examined cell-mediated immunity or reported on sex-based differences. To better understand sex-based differences in the immune response to mumps vaccine, we measured neutralizing antibody titers and mumps-specific cytokine/chemokine responses in a cohort of 748 adolescents and young adults after two doses of MMR vaccine. We observed significantly higher neutralizing antibody titers in females than in males (120.8 IU/mL, 98.7 IU/mL, p = 0.038) but significantly higher secretion levels of MIP-1α, MIP-1ß, TNFα, IL-6, IFNγ, and IL-1ß in males compared to females. These data demonstrate that sex influences mumps-specific humoral and cell-mediated immune response outcomes, a phenomenon that should be considered during efforts to improve vaccines and prevent future outbreaks.
Asunto(s)
Anticuerpos Antivirales/sangre , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Virus de la Parotiditis/inmunología , Vacunación , Adolescente , Quimiocinas/sangre , Niño , Estudios de Cohortes , Citocinas/sangre , Femenino , Humanos , Masculino , Caracteres Sexuales , Adulto JovenRESUMEN
Mumps is a vaccine-preventable disease caused by the mumps virus, but the incidence of mumps has increased among the children who were vaccinated with one-dose measles-mumps-rubella (MMR) in recent years. In this study, we analyzed the influence of different doses of mumps-containing vaccine (MuCV) against mumps using Cox-proportional hazard model. We collected 909 mumps cases of children who were born from 2006 to 2010 and vaccinated with different doses of MuCV in Quzhou during 2006-2018, which were all clinically diagnosed. Kaplan-Meier survival methods and Cox-proportional hazard model were used to estimate the hazard probabilities. Kaplan-Meier curves showed that the cumulative hazard of male and female has no difference; lower hazards were detected among those who were vaccinated with two-dose MuCV, born in 2006, and infected after supplementary immunization activities (SIA). Cox-proportional hazard regression suggested that onset after SIA, born in 2006, and vaccinated with two-dose MuCV were protective factors against infection even after adjusting for potential confounding effects. Our study showed that it was necessary to revise the diagnostic criteria of mumps and identify RT-PCR as the standard for mumps diagnosis in China. We suggested that routine immunization schedule should introduce two doses of MMR and prevaccination screening should be performed before booster immunization in vaccinated populations.
Asunto(s)
Sarampión/inmunología , Vacuna contra la Parotiditis/inmunología , Anticuerpos Antivirales/inmunología , Niño , Preescolar , China , Brotes de Enfermedades/prevención & control , Femenino , Humanos , Esquemas de Inmunización , Incidencia , Masculino , Paperas , Virus de la Parotiditis/inmunología , Modelos de Riesgos Proporcionales , Vacunación/métodosRESUMEN
On 16-17 January 2020, four suspected mumps cases were reported to the local Public Health Authorities with an epidemiological link to a local school and football club. Of 18 suspected cases identified, 14 were included in this study. Laboratory results confirmed mumps virus as the cause and further sequencing identified genotype G. Our findings highlight that even with a high MMR vaccine coverage, mumps outbreaks in children and young adults can occur. Since most of the cases had documented immunity for mumps, we hypothesise that waning immunity or discordant mumps virus strains are likely explanations for this outbreak.
Asunto(s)
Brotes de Enfermedades , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Virus de la Parotiditis/inmunología , Paperas/epidemiología , Adolescente , Niño , Brotes de Enfermedades/prevención & control , Femenino , Genotipo , Humanos , Masculino , Vacuna contra el Sarampión-Parotiditis-Rubéola/genética , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Paperas/prevención & control , Paperas/virología , Virus de la Parotiditis/genética , Virus de la Parotiditis/patogenicidad , Portugal/epidemiología , Vacunación/estadística & datos numéricos , Adulto JovenRESUMEN
Mumps is nowadays re-emerging despite vaccination. The contribution of T cell immunity to protection against mumps has not been clearly defined. Previously, we described a set of 41 peptides that were eluted from human leukocyte antigen (HLA) class I molecules of mumps virus (MuV)-infected cells. Here, we confirmed immunogenicity of five novel HLA-B*07:02- and HLA-A*01:01-restricted MuV T cell epitopes from this set of peptides. High frequencies of T cells against these five MuV epitopes could be detected ex vivo in all tested mumps patients. Moreover, these epitope-specific T cells derived from mumps patients displayed strong cytotoxic activity. In contrast, only marginal T cell responses against these novel MuV epitopes could be detected in recently vaccinated persons, corroborating earlier findings. Identifying which MuV epitopes are dominantly targeted in the mumps-specific CD8+ T- response is an important step towards better understanding in the discrepancies between natural infection or vaccination-induced cell-mediated immune protection.
Asunto(s)
Epítopos de Linfocito T/inmunología , Virus de la Parotiditis/inmunología , Paperas/inmunología , Linfocitos T Citotóxicos/inmunología , Adulto , Antígenos HLA-A/inmunología , Antígenos HLA-B/inmunología , Humanos , Paperas/prevención & control , Vacunación , Adulto JovenRESUMEN
The causative agent of mumps is a single-stranded, non-segmented, negative sense RNA virus belonging to the Paramyxoviridae family. Besides the classic symptom of painfully swollen parotid salivary glands (parotitis) in mumps virus (MuV)-infected men, orchitis is the most common form of extra-salivary gland inflammation. Mumps orchitis frequently occurs in young adult men, and leads to pain and swelling of the testis. The administration of MuV vaccines in children has been proven highly effective in reducing the incidence of mumps. However, a recent global outbreak of mumps and the high rate of orchitis have recently been considered as threats to male fertility. The pathogenesis of mumps orchitis remains largely unclear due to lack of systematic clinical data analysis and animal models studies. The alarming increase in the incidence of mumps orchitis and the high risk of the male fertility have thus become a major health concern. Recent studies have revealed the mechanisms by which MuV-host cells interact and MuV infection induces inflammatory responses in testicular cells. In this mini-review, we highlight advances in our knowledge of the clinical aspects and possible mechanisms of mumps orchitis.
Asunto(s)
Infertilidad Masculina/inmunología , Virus de la Parotiditis/inmunología , Paperas/inmunología , Orquitis/inmunología , Interacciones Huésped-Patógeno/inmunología , Humanos , Infertilidad Masculina/complicaciones , Infertilidad Masculina/prevención & control , Masculino , Paperas/complicaciones , Paperas/virología , Vacuna contra la Parotiditis/administración & dosificación , Vacuna contra la Parotiditis/inmunología , Virus de la Parotiditis/fisiología , Orquitis/complicaciones , Orquitis/virología , Factores de Riesgo , Vacunación/métodosRESUMEN
Numerous types of viruses have been found in human semen, which raises concerns about the sexual transmission of these viruses. The overall effect of semen on viral infection and transmission have yet to be fully investigated. In the present study, we aimed at the effect of seminal plasma (SP) on viral infection by focusing on the mumps viral (MuV) infection of HeLa cells. MuV efficiently infected HeLa cells in vitro. MuV infection was strongly inhibited by the pre-treatment of viruses with SP. SP inhibited MuV infection through the impairment of the virus's attachment to cells. The antiviral activity of SP was resistant to the treatment of SP with boiling water, Proteinase K, RNase A, and DNase I, suggesting that the antiviral factor would not be proteins and nucleic acids. PNGase or PLA2 treatments did not abrogate the antiviral effect of SP against MuV. Further, we showed that the prostatic fluid (PF) showed similar inhibition as SP, whereas the epididymal fluid and seminal vesicle extract did not inhibit MuV infection. Both SP and PF also inhibited MuV infection of other cell types, including another human cervical carcinoma cell line C33a, mouse primary epididymal epithelial cells, and Sertoli cell line 15P1. Moreover, this inhibitory effect was not specific to MuV, as the herpes simplex virus 1, dengue virus 2, and adenovirus 5 infections were also inhibited by SP and PF. Our findings suggest that SP contains a prostate-derived pan-antiviral factor that may limit the sexual transmission of various viruses.
Asunto(s)
Antivirales/inmunología , Células Epiteliales/inmunología , Virus de la Parotiditis/inmunología , Semen/inmunología , Virus/inmunología , Animales , Antivirales/metabolismo , Línea Celular Tumoral , Células Cultivadas , Chlorocebus aethiops , Células Epiteliales/metabolismo , Células Epiteliales/virología , Células HeLa , Interacciones Huésped-Patógeno/inmunología , Humanos , Masculino , Ratones Endogámicos C57BL , Virus de la Parotiditis/fisiología , Semen/metabolismo , Semen/virología , Células VeroRESUMEN
Although a live attenuated vaccine is available for controlling mumps virus (MuV), mumps still outbreaks frequently worldwide. The attenuated MuV vaccine strain S79 is widely used in mumps vaccination in China, but still with many shortcomings, among which the most prominent are the side effects and decreased immunity. Therefore, there is a need to further improve the safety and efficacy of the current MuV vaccine. In the present study, we further attenuated MuV S79 vaccine strain by inhibiting viral mRNA methyltransferase (MTase). We generated a panel of eight recombinant MuVs (rMuVs) carrying mutations in the MTase catalytic site or S-adenosylmethionine (SAM) binding site in the large (L) polymerase protein. These rMuVs are genetically stable and seven rMuVs are more attenuated in replication in cell culture and five rMuVs are more attenuated in replication in lungs of cotton rats compared with the parental vaccine strain S79. Importantly, cotton rats vaccinated with these seven rMuV mutants produced high levels of serum neutralizing antibodies and were completely protected against challenge with a wild-type MuV strain (genotype F). Therefore, our results demonstrate that alteration in the MTase catalytic site or SAM binding site in MuV L protein improves the safety or the immunogenicity of the MuV vaccine and thus mRNA cap MTase may be an effective target for the development of new vaccine candidates for MuV.
Asunto(s)
Metiltransferasas , Vacuna contra la Parotiditis , China , Metiltransferasas/genética , Virus de la Parotiditis/genética , Virus de la Parotiditis/inmunología , ARN Mensajero/genéticaRESUMEN
Leningrad-Zagreb strain of mumps vaccine virus was grown on two different cell substrates viz. MRC-5 cells and Vero cells besides its original cell substrate i.e. Chicken Embryo Cells. Homogeneous virus pools prepared from each set of experiments were then lyophilized as per standard in-house protocol. Critical Quality Attributes (CQAs) such as the titer of the bulk vaccine and potency and stability of the lyophilized vaccine were then estimated using the CCID50 method to understand the lyophilization losses and thermal losses respectively in the vaccine. Another CQA viz. the genetic homogeneity of the vaccine was also tested using the single base extension method for identifying the nucleotides present at the three known locations of single nucleotide polymorphism (SNP). Comparison of CQA results across different cell substrates indicated encouraging results for Vero cell grown L-Zagreb virus compared to the MRC-5 cells grown L-Zagreb mumps virus. Significant improvement in productivity was also observed in the dynamic culture conditions compared to the static culture conditions. Progressive work in this research area can lead to development of a cGMP manufacturing process for mumps vaccine with easy scale up potential in future.
Asunto(s)
Reactores Biológicos , Vacuna contra la Parotiditis/inmunología , Virus de la Parotiditis/inmunología , Paperas/inmunología , Animales , Línea Celular , Chlorocebus aethiops , Liofilización/métodos , Humanos , Paperas/prevención & control , Paperas/virología , Vacuna contra la Parotiditis/administración & dosificación , Vacuna contra la Parotiditis/normas , Virus de la Parotiditis/genética , Virus de la Parotiditis/fisiología , Control de Calidad , Vacunación , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/inmunología , Vacunas Atenuadas/normas , Células Vero , Cultivo de Virus/instrumentación , Cultivo de Virus/métodosRESUMEN
We report a case of suspected reinfection with the mumps virus in an elderly patient which resulted in temporary closure of an inpatient ward. A 65-year-old man with colorectal cancer was admitted to the digestive surgery ward at our hospital to undergo a stoma closure operation. He was subsequently referred to our department with right swelling in the preauricular region on postoperative day 4. The swelling subsided within a few days, and the patient was discharged. A serum titer test revealed a high level of antibodies to the mumps virus, however. Therefore, staff who had come into close contact with the patient were examined and the decision taken to stop admitting new patients to the ward. When symptoms are detected in a patient has already had mumps, it is important to consider the possibility of reinfection. Furthermore, it is necessary for medical workers to undergo a serum antibody test to the mumps virus and receive a further vaccination if antibody levels are too low to confer immunity.
Asunto(s)
Virus de la Parotiditis/inmunología , Paperas , Anciano , Anticuerpos Antivirales , Humanos , Pacientes Internos , MasculinoRESUMEN
Vaccine-preventable diseases (VPD) including measles and mumps have been re-emerging in countries with sustained high vaccine coverage. For mumps, waning immunity has been recognized as a major contributor to recent outbreaks. Although unvaccinated individuals account for most cases in recent measles outbreaks, the role of immune waning remains unclear. Accumulating serological and epidemiological evidence suggests that natural immunity induced by infection may be more durable compared to vaccine-induced immunity. As the proportion of population immunity via vaccination gradually increases and boosting through natural exposures becomes rare, risk of outbreaks may increase. Mechanistic insights into the coupled immuno-epidemiological dynamics of waning and boosting will be important to understand optimal vaccination strategies to combat VPD re-emergence and achieve eradication.
Asunto(s)
Vacuna Antisarampión/inmunología , Virus del Sarampión/inmunología , Sarampión/inmunología , Vacuna contra la Parotiditis/inmunología , Virus de la Parotiditis/inmunología , Paperas/inmunología , Animales , Humanos , Sarampión/epidemiología , Sarampión/virología , Vacuna Antisarampión/administración & dosificación , Vacuna Antisarampión/genética , Virus del Sarampión/genética , Paperas/epidemiología , Paperas/virología , Vacuna contra la Parotiditis/administración & dosificación , Vacuna contra la Parotiditis/genética , Virus de la Parotiditis/genéticaRESUMEN
BACKGROUND: Mumps outbreaks continue to occur in highly vaccinated populations. Although the diagnosis of mumps is primarily based on clinical symptoms, other viral infections such as parainfluenza can manifest in a similar manner. Therefore, laboratory confirmation of mumps virus infection is important. OBJECTIVES: The aims of this study were to examine mumps cases during the January 2018 to March 2019 period in Ireland as well as to evaluate the association between mumps RNA viral loads, mumps IgG levels, age and gender among patients with laboratory-confirmed mumps virus infection. STUDY DESIGN: Oral fluid samples requested for mumps RNA testing (nâ¯=â¯1296) were included in the study. The mumps N gene was detected by real time PCR and reported as Ct values. RESULTS: The proportion of samples received monthly with detectable mumps RNA increased from 10.26%-70.3% during the recent outbreak. Acute mumps cases occurred predominantly in the 16-25 years old age cohort (67.5 %) and in males (55.9 %). Mumps RNA viral loads were significantly higher in females (pâ¯<â¯0.001). During the outbreak, a significantly higher proportion of samples had Ct <30 (pâ¯<â¯0.05). A significant correlation was observed between mumps IgG levels and Ct values in oral fluid samples (pâ¯<â¯0.0001). CONCLUSIONS: The presence of low mumps virus-specific IgG in oral fluids is significantly associated with high mumps viral loads. Our findings show that mumps virus is maintained in circulation in the non-outbreak period and acute mumps cases occur predominantly in the MMR vaccinated young adult male population.
Asunto(s)
Paperas , Adolescente , Adulto , Anticuerpos Antivirales , Brotes de Enfermedades , Femenino , Humanos , Inmunoglobulina G , Masculino , Vacuna contra el Sarampión-Parotiditis-Rubéola , Paperas/epidemiología , Virus de la Parotiditis/inmunología , Carga Viral , Adulto JovenRESUMEN
BACKGROUND: Lebanon has experienced several measles and mumps outbreaks in the past 20 years. In this article, a case-based surveillance of both measles and mumps outbreaks in Lebanon was carried out in an attempt to outline factors contributing to the failure of elimination plans and to provide potential solutions. The relationship between the outbreaks of both diseases was described and explored. METHODS: A retrospective descriptive study of confirmed cases of measles and mumps in Lebanon between 2003 and 2018 collected from the Lebanese Ministry of Public Health Epidemiological Surveillance Unit public database was carried out. The information collected was graphically represented taking into consideration dates of reported cases, age groups affected, and vaccination status. RESULTS: The mean number of measles cases was 150.25 cases/year in the 1-4 years age group, 87 cases/year in individuals aging between 5 and 14, and 63.68 cases/year in those > 14 years old. In the latter group, only 18.05% were unvaccinated. The mean number of mumps cases was 30.4 cases/year in the < 4 year age group and 53.8 cases/year in the 10-19 years age group. During the study period, every spike in measles cases was followed by a similar spike in mumps. 9.66% of measles cases occurred in individuals who received at least 2 doses of the vaccine, 52.26% in the unvaccinated, and 38% in those whose vaccination status was undetermined. CONCLUSIONS: Measles in Lebanon is a disease of the pediatric population, but adults remain at risk. Outbreaks of mumps followed those of measles and were mainly among adolescents. Presence of a large number of Syrian refugees in the country may further complicate the situation. Vaccination activities need to be intensified.
Asunto(s)
Brotes de Enfermedades/prevención & control , Vacuna contra el Sarampión-Parotiditis-Rubéola/uso terapéutico , Sarampión/epidemiología , Sarampión/prevención & control , Paperas/epidemiología , Paperas/prevención & control , Vacunación/métodos , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Líbano/epidemiología , Masculino , Sarampión/virología , Morbillivirus/inmunología , Morbillivirus/aislamiento & purificación , Paperas/virología , Virus de la Parotiditis/inmunología , Virus de la Parotiditis/aislamiento & purificación , Vigilancia en Salud Pública , Refugiados , Estudios Retrospectivos , Adulto JovenRESUMEN
Between 18 August 2018 and 24 January 2020, 3,736 mumps cases were notified in Ireland. The highest numbers of notifications were observed in the age group 15-24 years. Vaccination status was reported for 32% (nâ¯=â¯1,199) of cases: 72% of these had received two doses of measles-mumps-rubella (MMR) vaccine. Vaccination uptake after free MMR vaccination targeting colleges and universities since early 2019 was low. Therefore, a national media campaign began in January 2020.
Asunto(s)
Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Paperas/epidemiología , Vacunación/estadística & datos numéricos , Adolescente , Distribución por Edad , Notificación de Enfermedades , Brotes de Enfermedades , Femenino , Humanos , Inmunización/estadística & datos numéricos , Incidencia , Irlanda/epidemiología , Estudios Longitudinales , Masculino , Paperas/diagnóstico , Paperas/inmunología , Virus de la Parotiditis/inmunología , Distribución por Sexo , Adulto JovenRESUMEN
Seroprevalence studies on measles, mumps, and rubella immunoglobulin G (IgG) antibodies after the implementation of the measles-mumps-rubella (MMR) vaccine are lacking in Kuwait. This study is an age-stratified serological study to assess the herd immunity to measles, mumps, and rubella among the young Kuwaiti population to evaluate the effectiveness of the MMR vaccine. IgG antibody titers to mumps, measles, and rubella were determined with commercial immune-assay in serum samples of 1000 Kuwaitis aged 5 to 20 years. The highest level of seropositivity was to measles (94.6%), which was significantly higher in females than in males. The highest seronegativity was for mumps (29%). The percentage of the young Kuwaiti population who were serologically positive for all the components of the MMR vaccine was 47%, and 2% of the individuals were without any protective antibodies to measles, mumps, and rubella. Females aged 5 to 10 years were best protected to rubella; however, seronegativity in 8.2% of 11- to 20-year-old females makes them vulnerable to rubella virus infection and congenital complications during pregnancy. The study provided insight into the effect of the MMR vaccine on seroprevalence of antibodies against measles, mumps, and rubella in Kuwait, which will contribute to the global knowledge base of vaccine coverage and help to inform elimination strategies. The findings strengthen the need for a third dose of MMR vaccine and catch-up campaigns for the young Kuwaiti population to increase vaccination coverage and prevent waning immunity, especially among those who received only one dose of the vaccine during childhood.
Asunto(s)
Anticuerpos Antivirales/sangre , Virus del Sarampión/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Virus de la Parotiditis/inmunología , Virus de la Rubéola/inmunología , Adolescente , Niño , Preescolar , Femenino , Humanos , Inmunidad , Inmunoglobulina G/sangre , Kuwait/epidemiología , Masculino , Sarampión/epidemiología , Sarampión/inmunología , Paperas/epidemiología , Paperas/inmunología , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/inmunología , Estudios Seroepidemiológicos , Adulto JovenRESUMEN
INTRODUCTION: A resurgence of mumps among fully vaccinated adolescents and young adults globally has led to questions about the longevity of vaccine derived specific immunity. Unfortunately, the ideal serological correlate of immunity to mumps has yet to be identified. However, neutralising antibody titres in serum are used extensively as a surrogate marker of immunity to mumps. Conventional neutralisation tests are technically challenging, thus we developed and validated a high throughput, RT-qPCR microneutralisation (RT-qPCR-MN) method to determine serum neutralising antibody levels to mumps virus strains which avoids a number of the technical limitations of existing methods. METHODS: The qPCR-MN assays were thoroughly validated using human serum samples from patients with prior exposure to mumps infection or vaccination. RESULTS: Each sample of pooled sera neutralised virus at a constant rate and without significant changes when tested against genotype A (MuV-A) and G (MuV-G) mumps virus concentrations from 200 to 3200 TCID50. The within run and between run variation of the RT-qPCR-MN assays for both genotypes were less than 3 % and 9 % for low and high titre samples, respectively. The correlation between the focus reduction neutralisation test and RT-qPCR-MN was excellent for both MuV-G (r2â¯=â¯0.80, 95CI: 0.67-1.00, pâ¯<â¯0.0001) and MuV-A genotypes (r2â¯=â¯0.88, 95 %CI 0.69-1.00, pâ¯<â¯0.0001) endpoint determinations. CONCLUSIONS: We have developed a RT-qPCR MN assay for mumps virus that is simple, fast, scientifically objective and has high throughput. The assay can be used to provide key insights into the efficacy of mumps vaccination, to help explain the causes for the resurgence of mumps infection in vaccinated populations.